NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors...
Original sourcePomerantz LLP is investigating Tandem for potential securities fraud. Malfunctions in insulin pumps could lead to serious medical issues. Tandem's stock fell nearly 20% following the safety alert. Investors are advised to join the class action investigation.
The investigation and safety concerns severely undermine investor confidence. Given the substantial price drop post-announcement, similar historical events have caused long-term damage to stock valuations.
Immediate investor sentiment is negatively impacted, but effects may dissipate over time like past recalls. Historical cases show long-term price recovery is possible, albeit slowly.
The investigation directly involves TNDM, affecting investor trust and future performance. Past recalls have shown significant market reactions.